Published in Clin Transl Imaging on February 12, 2015
Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci (2016) 0.80
Amyloid Imaging: Poised for Integration into Medical Practice. Neurotherapeutics (2017) 0.79
Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study. BMC Neurol (2015) 0.77
Feasibility and acceptance of simultaneous amyloid PET/MRI. Eur J Nucl Med Mol Imaging (2016) 0.76
Affinity of (nat/68)Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. Int J Mol Sci (2016) 0.75
Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. Psychiatry Investig (2016) 0.75
Feasibility of in vivo (18)F-florbetaben PET/MR imaging of human carotid amyloid-β. Eur J Nucl Med Mol Imaging (2017) 0.75
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Funct Neurol (2017) 0.75
Inter-rater variability of visual interpretation and comparison with quantitative evaluation of (11)C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging (2016) 0.75
Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst) (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol (2014) 5.61
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol (2012) 3.46
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain (2013) 1.09
PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med (2013) 1.08
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging (2011) 1.06
Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord (2012) 1.05
Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med (2013) 0.98
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatry (2014) 0.89
Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. J Nucl Med (2014) 0.89
Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET. Neuroimage (2013) 0.89
Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers. Eur J Nucl Med Mol Imaging (2012) 0.84
(18)F-florbetaben Aβ imaging in mild cognitive impairment. Alzheimers Res Ther (2013) 0.84
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests. J Alzheimers Dis (2013) 0.83
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol (2012) 0.82
Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging (2014) 0.80
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps. Int J Alzheimers Dis (2012) 0.77